scFv(CEA)-41BB-CD3zeta CAR-T Lentivirus

The scFv(CEA)-41BB-CD3ζ CAR-T lentiviral vector carries a second-generation chimeric antigen receptor specifically designed to recognize carcinoembryonic antigen (CEA). This receptor combines an anti-CEA single-chain variable fragment with a 4-1BB co-stimulatory module and a CD3ζ signaling domain. Based on a lentiviral backbone, this vector enables stable genomic integration and persistent CAR expression in both dividing and non-dividing cells, ensuring a stable and long-lasting phenotype in engineered T cells. The 4-1BB domain was chosen to promote T cell metabolic fitness, persistence, and memory phenotype, while also helping to mitigate excessive cytokine release associated with stronger activating co-stimulatory structures. This balance allows for robust activation and more sustained effector function of T cells under repeated antigen stimulation. The vector is designed to minimize promoter interference and transcriptional noise, thereby promoting uniform CAR expression across heterogeneous T cell populations. Furthermore, its broad tropism (e.g., through widely adopted pseudotyping strategies) supports efficient transduction of primary cells and common research cell models.

This lentiviral product is ideally suited for constructing CEA-targeted CAR-T cells to study their anti-tumor activity in various preclinical settings. Typical applications include in vitro cytotoxicity and cytokine release profiling against CEA-positive tumor models derived from colorectal cancer, gastric cancer, pancreatic cancer, and certain non-small cell lung cancers, as well as studying activation markers, antigen density thresholds, basal signaling, and exhaustion kinetics. It can be used to explore the unique persistence advantages of 4-1BB co-stimulation, assess serial killing capacity under repeated exposure, and dissect resistance mechanisms such as antigen downregulation or immunosuppressive signaling in the tumor microenvironment. Researchers can utilize it to establish stable CAR-expressing reference cell lines for standardizing assays, studying epitope selection and binding kinetics of the anti-CEA scFv, and supporting high-throughput screening to test small molecules or biologics that modulate T cell function.